These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 29045341)

  • 1. Effect of antihypertensive treatment on 24-h blood pressure variability: pooled individual data analysis of ambulatory blood pressure monitoring studies based on olmesartan mono or combination treatment.
    Omboni S; Kario K; Bakris G; Parati G
    J Hypertens; 2018 Apr; 36(4):720-733. PubMed ID: 29045341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan.
    Omboni S; Volpe M
    Adv Ther; 2019 Feb; 36(2):278-297. PubMed ID: 30591990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of combination therapies, including the angiotensin receptor blocker olmesartan and either a calcium channel blocker or a thiazide diuretic, in elderly patients with hypertension.
    Kato J; Yokota N; Tamaki N; Kariya S; Kita T; Ayabe T; Eto T; Kitamura K
    Hypertens Res; 2011 Mar; 34(3):331-5. PubMed ID: 21124326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
    Shimada K; Ogihara T; Saruta T; Kuramoto K;
    Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study.
    Matsui Y; O'Rourke MF; Hoshide S; Ishikawa J; Shimada K; Kario K
    Hypertension; 2012 Jun; 59(6):1132-8. PubMed ID: 22547439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olmesartan medoxomil combined with hydrochlorothiazide improves 24-hour blood pressure control in moderate-to-severe hypertension.
    Rosenbaum D; Girerd X
    Curr Med Res Opin; 2012 Feb; 28(2):179-86. PubMed ID: 22114906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension.
    Sellin L; Stegbauer J; Laeis P; Rump LC
    J Hypertens; 2005 Nov; 23(11):2083-92. PubMed ID: 16208152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amlodipine besylate/olmesartan medoximil fixed combination for the treatment of hypertension.
    Chrysant SG
    Expert Rev Cardiovasc Ther; 2009 Aug; 7(8):887-95. PubMed ID: 19673666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide.
    Chrysant SG; Weber MA; Wang AC; Hinman DJ
    Am J Hypertens; 2004 Mar; 17(3):252-9. PubMed ID: 15001200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic.
    Volpe M; Tocci G
    Vasc Health Risk Manag; 2012; 8():371-80. PubMed ID: 22745561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension.
    Chrysant SG; Marbury TC; Robinson TD
    J Hum Hypertens; 2003 Jun; 17(6):425-32. PubMed ID: 12764406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
    Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
    Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study of the efficacy of olmesartan/amlodipine vs. perindopril/amlodipine in peripheral blood pressure after missed dose in type 2 diabetes.
    Redon J; Pichler G;
    J Hypertens; 2016 Feb; 34(2):359-67. PubMed ID: 26867060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olmesartan medoxomil: current status of its use in monotherapy.
    Brunner HR
    Vasc Health Risk Manag; 2006; 2(4):327-40. PubMed ID: 17323586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly mild to moderate essential hypertensive patients with or without metabolic syndrome: a pooled post hoc analysis of two comparative trials.
    Omboni S; Malacco E; Mallion JM; Volpe M
    Drugs Aging; 2012 Dec; 29(12):981-92. PubMed ID: 23179896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of amlodipine/olmesartan ± hydrochlorothiazide in patients uncontrolled on prior calcium channel blocker or angiotensin II receptor blocker monotherapy.
    Neutel J; Shojaee A; Maa JF
    Adv Ther; 2012 Jun; 29(6):508-23. PubMed ID: 22773358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological interventions for hypertension in children.
    Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh R
    Evid Based Child Health; 2014 Sep; 9(3):498-580. PubMed ID: 25236305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The effects of olmesartan on ambulatory blood pressures and blood pressure variability in patients with mild to moderate essential hypertension].
    Li J; Qin T; Jiang H; Wang H; Ke Y
    Zhonghua Nei Ke Za Zhi; 2014 Oct; 53(10):788-92. PubMed ID: 25567150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study.
    Chrysant SG; Chavanu KJ; Xu J
    Am J Cardiovasc Drugs; 2009; 9(4):241-51. PubMed ID: 19655819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additional antihypertensive effect of drugs in hypertensive subjects uncontrolled on diltiazem monotherapy: a randomized controlled trial using office and home blood pressure monitoring.
    Karotsis AK; Symeonidis A; Mastorantonakis SE; Stergiou GS;
    Clin Exp Hypertens; 2006 Oct; 28(7):655-62. PubMed ID: 17060064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.